Abstract:Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of clinically aggressive diseases associated with poor prognosis. Except for ALK + anaplastic large-cell lymphoma (ALCL), most peripheral T-cell lymphomas are highly malignant and have an aggressive disease course and poor clinical outcomes, with a poor remission rate and frequent relapse after first-line treatment. Aberrant epigenetic alterations play an important role in the pathogenesis and development of specific types of peripheral T-cell lymphoma, including the regulation of the expression of genes and signal transduction. The most common epigenetic alterations are DNA methylation and histone modification. Histone modification alters the level of gene expression by regulating the acetylation status of lysine residues on the promoter surrounding histones, often leading to the silencing of tumour suppressor genes or the overexpression of proto-oncogenes in lymphoma. DNA methylation refers to CpG islands, generally leading to tumour suppressor gene transcriptional silencing. Genetic studies have also shown that some recurrent mutations in genes involved in the epigenetic machinery, including TET2, IDH2-R172, DNMT3A, RHOA, CD28, IDH2, TET2, MLL2, KMT2A, KDM6A, CREBBP, and EP300, have been observed in cases of PTCL. The aberrant expression of miRNAs has also gradually become a diagnostic biomarker. These provide a reasonable molecular mechanism for epigenetic modifying drugs in the treatment of PTCL. As epigenetic drugs implicated in lymphoma have been continually reported in recent years, many new ideas for the diagnosis, treatment, and prognosis of PTCL originate from epigenetics in recent years. Novel epigenetic-targeted drugs have shown good tolerance and therapeutic effects in the treatment of peripheral T-cell lymphoma as monotherapy or combination therapy. NCCN Clinical Practice Guidelines also recommended epigenetic drugs for PTCL subtypes as second-line therapy. Epigenetic mechanisms provide new directions and therapeutic strategies for the research and treatment of peripheral T-cell lymphoma. Therefore, this paper mainly reviews the epigenetic changes in the pathogenesis of peripheral T-cell lymphoma and the advancement of epigenetic-targeted drugs in the treatment of peripheral T-cell lymphoma (PTCL).

Mutations in Ras homolog family member A in patients with peripheral T-cell lymphoma and implications for personalized medicine

An Angioimmunoblastic T-cell Lymphoma Patient Presented as Persistent Hypereosinophilia With a Novel RHOA Mutation Encoding p. Ala161Glu

Genomics of Peripheral T-Cell Lymphoma and Its Implications for Personalized Medicine

Mutations Affecting Genes in the Proximal T-Cell Receptor Signaling Pathway in Peripheral T-Cell Lymphoma

Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes

Mutations of Epigenetic Modifier Genes As A Poor Prognostic Factor in Acute Promyelocytic Leukemia under Treatment with All-Trans Retinoic Acid and Arsenic Trioxide

Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma

TP53 and KMT2D mutations associated with worse prognosis in peripheral T‐cell lymphomas

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

Case Report: Pathogenesis With a Rare RHOA A161E Mutation in a Patient With Angioimmunoblastic T-Cell Lymphoma

Correlation of Mutational Landscape and Survival Outcome of Peripheral T-cell Lymphomas.

Mutations in Tyrosine Kinase and Tyrosine Phosphatase and Their Relevance to the Target Therapy in Hematologic Malignancies

New insights into the biology of T-cell lymphomas

How I treat the peripheral T-cell lymphomas

Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.

Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma

Current and upcoming treatment approaches to common subtypes of PTCL (PTCL NOS, ALCL, TFHs)

Genetic Landscape of Peripheral T-Cell Lymphoma

RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives

Biomarker-driven management strategies for peripheral T cell lymphoma

Single-cell heterogeneity and dynamic evolution of Ph-like acute lymphoblastic leukemia patient with novel TPR-PDGFRB fusion gene